Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,569.55 -25.08 (-0.55%) Dow
36,212.79 -32.71 (-0.09%) Nasdaq
14,180.65 -124.38 (-0.87%) Bitcoin USD
41,785.92 +2,199.20 (+5.56%) CMC Crypto 200
859.31 +0.60 (+0.07%)
Coherus BioSciences, Inc. (CHRS)
| Previous close | 2.3000 |
| Open | 2.3400 |
| Bid | 2.3000 x 1800 |
| Ask | 2.3100 x 2200 |
| Day's range | 2.2100 - 2.3700 |
| 52-week range | 1.4300 - 10.9910 |
| Volume | |
| Avg. volume | 4,492,047 |
| Market cap | 256.137M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5500 |
| Earnings date | 04 Mar 2024 - 08 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.00 |
GlobeNewswireCoherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone – -– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be available to NPC patients in the U.S. in January 2024 – REDWOO
Motley FoolWhy Coherus BioSciences Was Plummeting This Week
A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Market Intelligence, the healthcare company's share price had fallen by a steep 56% week to date. On Monday after market close, Coherus unveiled a set of third-quarter results that, despite a double-digit revenue increase, missed analyst estimates.
Motley FoolWhy Coherus Biosciences Stock Dropped Today
Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance. It generated $40 million of net sales of Cimerli, which treats retinal conditions -- up 50% from the prior quarter -- and $1.4 million from arthritis treatment Yusimry. Coherus highlighted its recently resubmitted biologic license application for Udenyca OnBody, its on-body injector presentation of Udenyca, after the completion and satisfactory resolution of a Food and Drug Administration (FDA) review of inspection findings at a third-party filler.
